BrosMed Medical Secures Hundreds of Millions in RMB in Series D Funding, Files for IPO

This round of financing will further accelerate BrosMed Medical's pace in research and development innovation and market expansion, promoting the company to develop to a higher level.

The investors highly recognized BrosMed Medical's technical strength and market prospects, and looked forward to deep cooperation in the healthcare field between both parties in the future.

This round of financing is BrosMed Medical's2020YearCA new round of capital boost after the financing round. Public information shows,The registered capital of the company has been increased to5782.0355RMB million, demonstrating its continuously growing capital value。

Wu Zhipeng from Star Bridge Capital stated: "We are very honored to assist BrosMed Medical in completing this round of financing. The company, with its international strategic layout, excellent product performance, and efficient mass production capabilities, has achieved remarkable results in just a few years. We firmly believe that this financing will further consolidate the company's leading position in the industry and continue to lead industrial transformation and technological innovation."

# Industrial Layout:The Largest Balloon Catheter Manufacturer in China

Industry Status and Technical Accumulation

BrosMed Medical was founded in2012Year, headquartered in Dongguan Songshan Lake High-Tech Zone,Is the largest domestic producer of vascular interventional balloon catheters in China.。

Among China-produced vascular interventional device companies, itsProduction and sales account for more than50%, accounting for70%Above。

The company has built a coverageCoronary Intervention, Peripheral Intervention, Vascular Access, NeurointerventionFour Major Fields40More than 10 product series, holding global360Yu Zhangsan Class III Medical Device Registration Certificate (IncludingCE、FDA、PMDACertification), products are marketed globally80More than 100 countries and regions.

In China, BrosMed Medical has obtained a total of31Registration Certificate(Including Shanghai Maikang), among which there are many balloon products17Payment： 

BrosMed Medical's core product lines mainly focus on vascular interventional medical devices, specifically including cardiovascular intervention, peripheral vascular intervention, vascular access, and interventional accessories, among other fields.

Its technical fieldInBalloon Dilation CatheterAt the core, covering a variety of advanced interventional treatment technologiesSuch as coronary balloon catheters, high-pressure non-compliant balloons, semi-compliant balloons, etc., widely used in complex cardiovascular disease treatments such as percutaneous transluminal coronary angioplasty (PTCA) and chronic total occlusion (CTO).

Technically, BrosMed MedicalTheThe core team is one of the earliest teams in China to engage in the development and production of high-end vascular interventional medical devices, and is among the few top-tier global coronary teams.One of the balloon catheter technology teams.

The company ownsIn GuangdongProvincial Vascular Interventional Therapy Technology and Device Engineering Research Center &CNASCertified laboratory, mastering world-leading balloon catheter manufacturing technology, with intellectual property exceeding150Item.

2024In that year, the first phase of its global headquarters base was topped off. After production begins, it is expected to achieve an annual capacity of millions of units and an annual output value of billions of yuan.

Innovation Cooperation and Breakthrough in Domestic Substitution

2025Year2Month, BrosMed Medical and internationally renowned medical device companyCordis(ContiThink)Reach CooperationThe two parties will jointly promote the localized production of peripheral vascular drug balloons in China.

The key focus of this collaboration lies in"Zero Chipping" TechnologyDevelopment and Application, this technology is considered the core bottleneck for whether drug-coated balloon products can achieve widespread clinical application.

According to public information, drug-coated balloons are mainly used forTo prevent blood vessels from narrowing again, the stability of drug loading, release efficiency, and safety highly depend on coating technology.Prior to this, domestically, the field mainly relied on imported products, which were expensive and had limited accessibility.

This time, BrosMed Medical andCordisThe cooperation is interpreted by the industry as a signal that domestically produced high-end interventional devices are launching a substantive challenge in the core technology field.

# China-Made Substitutes: Game Changers in the Cardiovascular Device Market

Cardiovascular disease treatment is the second largest sector in the global medical device industry.

According toAccording to statistics from Frost & Sullivan,In 2021, the market for cardiovascular interventional devices in China reached 37.204 billion RMB,By 2030, the market size will reachRMB 140.179 billion, with a compound annual growth rate of 15.88% from 2021 to 2030.

▲Data source: Frost & Sullivan

But in China-produced vascular intervention products,Currently onlyCoronary StentAchieved a high level of domestic substitution, the localization rate in China has exceeded80%。

Balloon CatheterTube GuidanceHigh-value disposable silk-like medical consumables, due to high technical barriers and stringent production process requirements, have seenImport substitution for implantable stent products has been basically completed.However, products such as coronary balloon catheters and guidewires are still monopolized by imports.The inverted pattern.

Market data shows,In the field of coronary artery access devices, the market is mainly dominated by foreign brands such as Terumo, Medtronic, and Abbott., especially for domestically produced registered products such as guidewires, guiding catheters, and microcatheters, the market share is less than that of foreign brands.1/3, with huge space for domestically produced alternatives.

In the field of peripheral vascular intervention, domestically produced products are even more scarce. Whether it is arterial or venous, the main market share is still occupied by foreign companies such as Medtronic, Gore, and Cook Medical, with their market share being as high as95%。

BrosMed Medical is becoming a strong challenger in this market landscape with its technological innovation and product quality. The company’s products have filled the gap in the bottleneck of domestically produced balloon technology and scale, creating several internationally pioneering products with advanced global standards, thereby promoting the process of domestic substitution.

# CapitalAssist: FromCIt's one's turnDWheel's Acceleration Run

A review of BrosMed Medical's financing journey shows that the company has been...2014After completing the Series A financing round in the year,10Continued to receive attention and support from the capital market within the year.As of now, a total of5Round of Financing。

BrosMed Medical's capital journey began2013End of the year2014At the beginning of the yearAIn this round of financing, TC Capital and an investment institution in Foshan invested tens of millions of yuan in the company.

2015In the year, the company completed tens of millions of yuan.BRound of financing, with investors including Cowin Venture, Nanjing Hengtong Asset Management Co., Ltd., TOHOLD Donghai and an institution with American background.

2020Year7In the month, BrosMed Medical completed a financing of several hundred million yuan.CThis round of financing was led by Hillhouse Ventures, with participation from Cathay Capital, China Services Trade Fund, and Northern Light Venture Capital. Notably, this financing was completed in less than four months, which is particularly remarkable given the severe challenges posed by the COVID-19 pandemic.

2025Year6Month'sDRound of financing, byIDGCapital, Singularity Capital, Mirae Asset, and Ronghui Capital jointly participated in the investment, marking the capital market's high recognition of BrosMed Medical's technical strength and market prospects.

The funds from multiple rounds of financing will be mainly used to advance the company's product development, market promotion, and expanded reproduction, providing strong momentum for the company's sustainable development.

The specific financing situation displayed on Tianyancha is as follows:

Welcome companies to actively participate in the conference organized by Siyu ↓

July 17, 2025, The 2nd Global Medical Technology Conference

September 4-5, 2025, The 3rd Global Surgical Robotics Conference